FY2025 · ended Dec 31, 2025 · Revenue $9.47B, +2.3% YoY · Filed Feb 12, 2026
Zoetis Inc. (ZTS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.5 billion and net income of $2.7 billion. Free cash flow was $2.3 billion. As of Jun 30, 2026 it held $1.7 billion in cash and investments and $9.2 billion in total debt.
Revenue (TTM)
$9.53B
+1.6% vs year-ago TTM
Net income (TTM)
$2.64B
+1.8% vs year-ago TTM
Operating cash flow (TTM)
$2.84B
-4.6% vs year-ago TTM
Free cash flow (TTM)
$2.32B
+2.1% vs year-ago TTM
EPS (TTM)
$6.12
+6.2% vs year-ago TTM
Dividend per share (TTM)
$2.09
+8.2% vs year-ago TTM
Shares outstanding
422.13M
-5.7% vs prior year
Net cash
$-7.56B
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZTS (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Parsippany, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1555280
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B |
| Net income | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B |
| Diluted EPS | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
| Operating cash flow | $2.9B | $3.0B | $2.4B | $1.9B | $2.2B |
| Free cash flow | $2.3B | $2.3B | $1.6B | $1.3B | $1.7B |
| Total assets | $15.5B | $14.2B | $14.3B | $14.9B | $13.9B |
| Total liabilities | $12.1B | $9.5B | $9.3B | $10.5B | $9.4B |
| Stockholders' equity | $3.3B | $4.8B | $5.0B | $4.4B | $4.5B |
| Cash and investments | $2.3B | $2.0B | $2.0B | $3.6B | $3.5B |
| Total debt | $9.3B | $6.8B | $6.8B | $8.1B | $6.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 13, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 22, 2026 | May 20, 2026 |
All 1002 Zoetis Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.